Form 4: Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Reports Stock Option Grant and RSU Transactions

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs), as well as the sale of shares to cover withholding taxes.

Summary

• On March 24, 2025, Mark C. Schneyer, the EVP and CFO of Acadia Pharmaceuticals, was granted stock options for 110,761 shares at an exercise price of $17.23.
• These options vest 25% on March 24, 2026, and the remainder in 36 equal monthly installments.
• Schneyer also acquired 32,552 restricted stock units (RSUs) that vest in four equal annual installments beginning March 24, 2026.
• Additionally, 6,178 RSUs vested on March 25, 2025, and Schneyer sold 3,171 shares on March 26, 2025, at $17.05 per share to cover withholding taxes related to the vesting of RSUs.
• Following these transactions, Schneyer directly owns 56,889 shares of Acadia Pharmaceuticals common stock and 18,536 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports transactions related to executive compensation, which are standard business practices.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules for the options and RSUs encourage long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the stock options and RSUs suggest a long-term commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Vesting schedules typically range from three to five years, with annual or monthly vesting increments.
• The sale of shares to cover withholding taxes is a standard practice when RSUs vest.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by increasing the number of shares outstanding.
• The stock option and RSU grants incentivize the CFO to work towards the long-term success of the company, which benefits all stakeholders.

Key Dates

Keywords

Acadia Pharmaceuticals, Mark C. Schneyer, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, Insider Trading